This is a Demo Server. Data inside this system is only for test purpose.
 

Therapeutic potentials of fisetin, hesperetin and vitexin on chronic myeloid leukemia and acute myeloid leukemia cells

dc.authoridTR115412en_US
dc.contributor.advisorBaran, Yusufen_US
dc.contributor.authorAdan Gökbulut, Aysun
dc.date.accessioned2023-11-16T12:13:43Z
dc.date.available2023-11-16T12:13:43Z
dc.date.issued2015
dc.departmentMolecular Biology and Geneticsen_US
dc.descriptionThesis (Doctoral)--Izmir Institute of Technology, Molecular Biology and Genetics, Izmir, 2015en_US
dc.descriptionIncludes bibliographical references (leaves: 86-101)en_US
dc.descriptionText in English; Abstract: Turkish and Englishen_US
dc.descriptionxi, 101 leavesen_US
dc.description.abstractFisetin, hesperetin and vitexin are plant-derived flavonoids. This thesis study aims to investigate therapeutic potentials of them on human HL60 APL and K562 CML cells since there are no studies on these cells. The effects of these compounds on APL and CML cells have been considered in terms of cytotoxicity, apoptosis and cell cycle progression. In this study, genome-wide microarray analysis has been also performed for APL and CML cells to identify the genes and networks that are responsible for fisetin and hesperetin-induced effects. In summary, we intented to explain the molecular mechanisms and global gene expression patterns related with the effects of these flavonoids on both APL and CML for the first time. There were decreases in the viability/proliferation of K562 and HL60 cells treated with fisetin, hesperetin and vitexin. Fisetin was the most effective flavonoid for the induction of apoptosis in both cells. Fisetin, hesperetin and vitexin have been found to affect cell cycle progression at different phases of the cell cycle in both CML and AML cells, thus having cytostatic effects. In conclusion, the results of this study indicated that especially fisetin and hesperetin may have therapeutic potential in APL and CML cells due to induction of apoptosis, inhibition of cell proliferation and cell cyle arrest. Moreover, the genetic networks derived from this study illuminate some of the biological pathways affected by fisetin and hesperetin treatment while providing a proof of principle for identifying candidate genes that might be targeted for CML and APL therapy.en_US
dc.identifier.citationreferenceAdan Gökbulut, A. (2015). Therapeutic potentials of fisetin, hesperetin and vitexin on chronic myeloid leukemia and acute myeloid leukemia cells.Unpublished doctoral dissertation, İzmir Institute of Technology, İzmir, Turkeyen_US
dc.identifier.urihttp://standard-demo.gcris.com/handle/123456789/6349
dc.institutionauthorAdan Gökbulut, Aysun
dc.language.isoenen_US
dc.oaire.dateofacceptance2015-01-01
dc.oaire.impulse0
dc.oaire.influence2.9837197E-9
dc.oaire.influence_alt0
dc.oaire.is_greentrue
dc.oaire.isindiamondjournalfalse
dc.oaire.keywordsGenetics
dc.oaire.keywordsGenetik
dc.oaire.keywordsBiology
dc.oaire.keywordsBiyoloji
dc.oaire.popularity1.1832216E-9
dc.oaire.popularity_alt0.0
dc.oaire.publiclyfundedfalse
dc.publisherIzmir Institute of Technologyen_US
dc.relation.publicationcategoryTezen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCancer cellsen_US
dc.subjectLeukemiaen_US
dc.subjectFlavonesen_US
dc.titleTherapeutic potentials of fisetin, hesperetin and vitexin on chronic myeloid leukemia and acute myeloid leukemia cellsen_US
dc.title.alternativeFisetin, hesperetin ve viteksinin kronik miyeloid lösemi ve akut miyeloid lösemi hücreleri üzerine terapötik potansiyellerien_US
dc.typeDoctoral Thesisen_US
dspace.entity.typePublication

Files

Collections